FDA posts safety alerts, public health advisories, press releases and other notices from companies as a service to health professionals, consumers and other interested parties. Although FDA approves medical products, FDA does not endorse either the product or the company.
SERONO STATEMENT REGARDING COUNTERFEIT SEROSTIM®
Norwell, MA, January 22, 2001 — Serono, Inc., in cooperation with the U.S. Food and Drug Administration (FDA), is informing patients, physicians and distributing pharmacies about a counterfeit version of Serono’s SerostimÒ 6mg [somatropin (rDNA origin) for injection]. Serostim® is approved for the treatment of AIDS wasting.
Unlike genuine SerostimÒ 6mg, the counterfeit product is of unknown safety and efficacy and may pose a health risk to patients. The counterfeit product, which is definitely not SerostimÒ , was neither manufactured nor distributed by Serono.
Serono recently became aware of the existence of the counterfeit drug. Serono has issued a "Notification of Potential Counterfeit Product" to wholesalers, pharmacists, physicians and AIDS service organizations to alert them, in an effort to prevent patients currently undergoing SerostimÒ therapy from receiving the counterfeit product. The counterfeit product has been packaged to appear as drug product lot number MNK612A and is readily distinguishable from authentic SerostimÒ by the following features:
Features of Counterfeit lot #MNK612A 7-Pack Box:
|
Features of Authentic lot #MNK612A
|
Serostim ® Vial:
|
|
Diluent Vial :
|
|
FDA’s Office of Criminal Investigations is actively investigating this matter. Serono is cooperating fully with federal authorities to stop the distribution of the counterfeit product and to prosecute those responsible for it.
CONTACT:
Carolyn Castel, Serono, Inc. - 781- 681-2340
Laura Bradbard, US Food and Drug Administration - 301-827-6242
HTML by JLW